无血清狂犬病疫苗模拟暴露后程序的免疫原性与安全性Ⅲ期试验
该随机双盲阳性对照Ⅲ期试验纳入2000名10-60岁健康人,比较Sinovac无血清狂犬病疫苗5剂Essen程序与两种简化4剂程序。易感人群接种后D14、D28、D42血清阳转率均达100%,D14中和抗体几何平均浓度在各疫苗组为33.17-37.38 IU/mL,三组均达非劣效标准。安全性各组相当,多数不良反应为1级,未报告疫苗相关严重不良事件。
要点
- 无血清狂犬病疫苗5剂及两种4剂程序在易感人群中D14血清阳转率均达100%。
- D14中和抗体GMC在两种4剂组、5剂组和对照组分别为36.36、33.17、34.71、37.38 IU/mL。
- 所有Sinovac疫苗组均达到D14和D42血清阳转率及D14 GMC的非劣效标准。
核心结论
- Sinovac无血清狂犬病疫苗在5剂Essen程序和两种简化4剂程序下均诱导快速、强效且持久的免疫应答,安全性良好。
研究设计与样本
- 随机、双盲、阳性对照Ⅲ期临床试验,纳入2000名10-60岁健康受试者,按1:1:1:1随机分为5剂研究组、4剂研究组1(D0,3,7,14)、4剂研究组2(D0,3,7,28)和5剂对照组。
主要发现
- 易感受试者(基线狂犬病毒中和抗体<0.5 IU/mL)中,所有组D14、D28、D42血清阳转率均达100%。
- D14中和抗体GMC在4剂研究组1、4剂研究组2、5剂研究组和对照组分别为36.36、33.17、34.71、37.38 IU/mL。
- 所有Sinovac疫苗组在D14和D42血清阳转率及D14 GMC方面均达到预设的非劣效标准。
- 所有Sinovac疫苗组3个月时血清阳性率维持100%,6个月时高于97%。
- 安全性各组相当,多数不良反应为1级,未报告疫苗相关严重不良事件。
临床怎么用
- 简化4剂程序(D0,3,7,14或D0,3,7,28)可作为暴露后预防的候选方案,有助于提高接种依从性和可及性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Rabies is a fatal zoonotic disease that can be effectively prevented through timely postexposure prophylaxis (PEP). Serum-free rabies vaccines may theoretically reduce risks associated with animal-derived components, and simplified PEP schedules may improve vaccination compliance and accessibility. This trial evaluated the immunogenicity and safety of Sinovac serum-free rabies vaccine administered using 5-dose and simplified 4-dose schedules. METHODS: A randomized, double-blind, active-controlled phase III clinical trial was conducted in 2000 healthy participants aged 10-60 years. Participants were randomized in a 1:1:1:1 ratio to receive Sinovac rabies vaccine according to the 5-dose Essen schedule on D0,3,7,14,28 (5-dose study group), two 4-dose schedules on D0,3,7,14 (4-dose study group 1) or D0,3,7,28 (4-dose study group 2), or a licensed rabies vaccine according to the 5-dose Essen schedule (5-dose control group). Primary endpoints were seroconversion rates (SCRs) and geometric mean concentrations (GMCs) on D14 and SCRs on D42 in susceptible participants with baseline rabies virus neutralizing antibodies (RVNA) <0.5 IU/mL. Secondary endpoints included SCR and GMC on D28, seropositive rates at 3 and 6 months, and safety through 6 months. RESULTS: In susceptible participants, SCRs reached 100% on D14, D28, and D42 in all groups. On D14, RVNA GMCs were 34.71, 36.36, 33.17, and 37.38 IU/mL in the two 4-dose study groups, 5-dose study group, and the control group, respectively. All three Sinovac vaccine groups met the prespecified non-inferiority criteria versus the control group for D14 and D42 SCRs and D14 GMCs. Seropositive rates remained 100% at 3 months and above 97% at 6 months in all Sinovac vaccine groups. Safety profiles were comparable across groups, and most adverse reactions were Grade 1, with no vaccine-related serious adverse events reported. CONCLUSIONS: Sinovac serum-free rabies vaccine induced rapid, robust, and persistent immune responses under both 5-dose and simplified 4-dose schedules, with a favorable safety profile.
引用
- Jing Y, Chang X, Jin Z, et al. Immunogenicity and safety of serum-free rabies vaccine for human use with simulated post-exposure schedules: A randomized, double-blind, active-controlled phase III clinical trial. Vaccine. 2026. PMID: 42456561. doi:10.1016/j.vaccine.2026.128914
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。